Is OXGN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

398 people get OXGN articles and Market Currents by email alert.

Get email alerts on OXGN »

HEADLINES:

OXiGENE Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 6
OXiGENE Reports First Quarter 2013 Financial Results

GlobeNewswire (May 6, 2013)
OXiGENE's Oncology Drugs Have Run Their Course
Bay Area Biotech • Wed, May 1 • 2 Comments
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial

GlobeNewswire (Apr 24, 2013)
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast

GlobeNewswire (Apr 24, 2013)
OXiGENE Announces $5 Million Private Placement

GlobeNewswire (Apr 11, 2013)
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

GlobeNewswire (Mar 20, 2013)
OXiGENE Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
OXiGENE Reports Full Year 2012 Financial Results

GlobeNewswire (Mar 12, 2013)
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast

GlobeNewswire (Mar 4, 2013)
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial

GlobeNewswire (Feb 6, 2013)
OXiGENE Announces Presentation at BIO CEO Conference on February 12th

GlobeNewswire (Feb 4, 2013)
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

GlobeNewswire (Jan 23, 2013)
OXiGENE Regains Nasdaq Closing Bid Price Compliance

GlobeNewswire (Jan 16, 2013)
OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting

GlobeNewswire (Dec 10, 2012)
Risk Vs. Reward: 2 Biotech Stocks I'm Considering In The Wake Of Recent Developments
Matt Schilling • Fri, Nov 23, 2012 • 5 Comments
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia

GlobeNewswire (Nov 21, 2012)
OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting

GlobeNewswire (Nov 12, 2012)
OXiGENE's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012

To learn more about Seeking Alpha Pro, click here.

OXiGENE's Oncology Drugs Have Run Their Course
Bay Area Biotech • Wed, May 1 • 2 Comments
Oxigene Headed Back Down On Disappointing Zybrestat Results
GuruFundPicks • Fri, Nov 4, 2011 • 1 Comment
Why Speculators Are Buzzing About OxiGENE
M. E. Garza • Mon, Oct 31, 2011 • 2 Comments
Oxigene Is Up 60% On Wild Speculation But It's Bound To Decline
GuruFundPicks • Thu, Oct 20, 2011 • 3 Comments
Oxigene Gains 7% on 10x Volume
H.S. Ayoub • Mon, Apr 23, 2007

Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Risk Vs. Reward: 2 Biotech Stocks I'm Considering In The Wake Of Recent Developments
Matt Schilling • Fri, Nov 23, 2012 • 5 Comments
Bear Raids And Tree Shaking In Biotechnology And Drugs
Joe Springer • Tue, Aug 7, 2012 • 13 Comments
4 Pharmaceutical Companies Moving On News
Markus Aarnio • Mon, Aug 6, 2012 • 2 Comments
ASCO Stocks To Consider This Week
Jessica King Holden • Tue, May 29, 2012 • 2 Comments
3 Biopharma Picks: A Certain Level Of Risk Is Required
Matt Schilling • Wed, Mar 28, 2012 • 1 Comment
Small-Cap Biotech Picks By The World's Largest Fund Managers
GuruFundPicks • Tue, Oct 25, 2011 • 4 Comments
Will the Next Apple or Google Be Found Among These Micro Caps?
Kurtis Hemmerling • Thu, Aug 18, 2011 • 9 Comments
7 Big Movers That Investors Must Watch This Week
NakedValue • Mon, Jun 6, 2011 • 1 Comment
3 Small Cap Biotechs Primed For Corrections
TheMarketFinancial • Mon, May 16, 2011 • 4 Comments
A Simplified ASCO 2011 List for Biotech Investor Research
Chemistfrog • Mon, May 9, 2011 • 2 Comments
ASCO 2011: Opportunities for Biotech Investor Success and Failure
Chemistfrog • Mon, May 2, 2011 • 7 Comments
8 Cancer Innovators to Watch
Douglas Cress • Tue, Nov 9, 2010 • 13 Comments
Three Promising Small-Cap Cancer Plays
Justin M. Hall • Mon, May 17, 2010 • 22 Comments
Human Genome Sciences Antibody Fails: Biotech's Weekly Round-Up of Missed Targets
The Burrill Report • Sun, Mar 21, 2010
Boston Scientific to Cut up to 1,300 Employees: Biotech's Weekly Mishaps Report
The Burrill Report • Mon, Feb 15, 2010 • 1 Comment
Interview: Greenbackd Sees Big Storm Clouds Everywhere
Miguel Barbosa • Wed, Oct 28, 2009 • 4 Comments
Cancer Stocks Hammered Once Again
Alan Brochstein • Tue, Jun 26, 2007 • 7 Comments
Cancer Stocks Slide Again
Alan Brochstein • Mon, Jun 18, 2007 • 1 Comment
Cancer Stocks Plunge Following ASCO Meeting
Alan Brochstein • Mon, Jun 11, 2007 • 3 Comments

OXiGENE Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 6
OXiGENE Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
OXiGENE's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
OxiGene, Inc. Q2 2008 Earnings Call Transcript
Mon, Aug 4, 2008

OXiGENE Reports First Quarter 2013 Financial Results

GlobeNewswire (May 6, 2013)
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial

GlobeNewswire (Apr 24, 2013)
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast

GlobeNewswire (Apr 24, 2013)
OXiGENE Announces $5 Million Private Placement

GlobeNewswire (Apr 11, 2013)
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

GlobeNewswire (Mar 20, 2013)
OXiGENE Reports Full Year 2012 Financial Results

GlobeNewswire (Mar 12, 2013)
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast

GlobeNewswire (Mar 4, 2013)
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial

GlobeNewswire (Feb 6, 2013)
OXiGENE Announces Presentation at BIO CEO Conference on February 12th

GlobeNewswire (Feb 4, 2013)
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

GlobeNewswire (Jan 23, 2013)
OXiGENE Regains Nasdaq Closing Bid Price Compliance

GlobeNewswire (Jan 16, 2013)
OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting

GlobeNewswire (Dec 10, 2012)
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia

GlobeNewswire (Nov 21, 2012)
OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting

GlobeNewswire (Nov 12, 2012)
OXiGENE Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 8, 2012)
OXiGENE Announces Presentation at BIO-Europe Conference on November 14th

GlobeNewswire (Nov 5, 2012)
OXiGENE Announces Third Quarter 2012 Earnings Conference Call and Webcast

GlobeNewswire (Nov 1, 2012)
OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer

GlobeNewswire (Sep 17, 2012)
OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat(R) in Anaplastic Thyroid Cancer

GlobeNewswire (Sep 7, 2012)
OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta A/S

GlobeNewswire (Aug 22, 2012)

OXGN vs. ETF Alternatives

Company Description

Currently, there's no company description for OXGN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, April 9, 4:55 PM OXiGENE (OXGN) is exploring regulatory approval for Zybrestat to treat anaplastic thyroid cancer in the European Union with a marketing authorization application under an exceptional or conditional circumstances pathway. The special conditions would allow it to receive approval without conducting another clinical trial and for substantially less cost. Shares -2% AH. Comment! [Healthcare, On the Move, Global & FX]
Thursday, March 21, 10:55 AM OXiGENE (OXGN +4%) bucks a weak tape to trade higher today, after announcing late yesterday that it's been issued a patent by the USPTO covering certain benzosuberene-based compounds, including the analogues referred to as KGP18 and KGP156 that the company is currently developing in the preclinical stage. The patent also covers methods of using those compounds to reduce blood flow to a tumor, and possibly restrain, slow, stop or reverse tumor progression. Comment! [Healthcare, On the Move]
Thursday, February 7, 1:05 PM Midday top 10 gainers: SUTR +40%. FMFC +39%. OXGN +23%. VSAT +22%. TRLG +20%. GEOS +20%. DV +18%. ARKR +17%. PLNR +16%. SCKT +15%.
Midday top 10 losers: AKAM -16%. ADEP -16%. EPAX -15%. OSUR -14%. SGMO -14%. IRBT -13%. ATML -13%. BONT -13%. RTIX -13%. PSMI -12%. Comment! [On the Move]
Thursday, February 7, 9:29 AM Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well tolerated when used in conjunction with Roche's Avastin in a Phase II trial, with no additional safety concerns. Oxigene expects patient accrual for the study to be completed within the next 3-4 months and for top-line data to be available at the end of the year. (PR) Comment! [Healthcare, On the Move]
Thursday, February 7, 9:14 AM Premarket gainers: OXGN +31%. SUTR +29%. DV +18%. BIOL +9%. AAP +9%. ORLY +9%. APPY +7%. LF +6%.
Losers: AKAM -18%. TQNT -11%. ARAY -9%. ANN -9%. GMCR -9%. NXST -6%. BBEP -6%. MWW -6%. BG -5%. ATML -5%. Comment! [On the Move]
Tuesday, November 20, 2012, 2:19 PM OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients with polypoidal choroidal vasculopathy, suggest that the drug, even if administered only as a single dose intravenously, may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with disease. The company also notes that further clinical testing with a more practical topical formulation in combination with photodynamic therapy may be warranted for further testing. Comment! [Healthcare, On the Move]
Tuesday, November 13, 2012, 1:06 PM Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its Phase 2 trial of Zybrestat, a potential treatment for patients with polypoidal choroidal vasculopathy, a degenerative eye disease with features similar to age-related macular degeneration. The data was presented today at the annual meeting of the American Academy of Ophthalmology. 1 Comment [Healthcare, On the Move]
Monday, September 17, 2012, 4:23 PM OXiGENE (OXGN) and the FDA reach a deal on a special protocol assessment for the Phase 3 trial of its thyriod cancer drug zybrestat. Shares +14.8% AH. 2 Comments [Healthcare, On the Move]
Wednesday, August 22, 2012, 4:13 PM Oxigene (OXGN) expands its zybrestat patient program with Azanta A/S to include the additional territories of Israel and South Korea, thus expanding on its existing regions consisting of the European Union, the Nordic countries, Switzerland, and Canada. Under the terms of the agreement, OXGN will provide Zybrestat to Azanta, and Azanta then serves as the exclusive distributor in the specified territory. Comment! [Healthcare]
Monday, August 6, 2012, 11:44 AM Oxigene (OXGN +17.5%) pops after saying its randomized Phase 2 study evaluating the combination of zybrestat and bevacizumab to treat patients with advanced ovarian cancer achieved important safety objectives in a scheduled interim toxicity analysis, and it's expected to continue to full enrollment. Comment! [Healthcare, On the Move]
Thursday, November 3, 2011, 6:51 PM Oxigene (OXGN) shares tumble over 35% after hours following a mixed report on its Phase 2 study of its cancer drug Zybrestat. Although tests appear to show some improvement when combined with other treatments, the drug shows no discernible survival benefit in stand-alone form. Comment! [On the Move, Healthcare]
Thursday, September 1, 2011, 10:43 AM Oxigene (OXGN -23%) sinks to a new 52-week low after halting Phase 2 and 3 studies of its thyroid cancer drug candidate Zybrestat due to lack of funding, and announces a restructuring whereby it will reduce its workforce by 60%. Comment! [Healthcare, On the Move]
Monday, June 6, 2011, 9:57 AM A good day for Oxigene (OXGN +18.5%), as shares soar on news that the biotech firm is again in compliance with Nasdaq minimum market and stock value requirements, and the company reports encouraging data on a phase 2 trial of its Zybrestat non-small cell lung cancer drug. Comment! [Healthcare, On the Move]
Tuesday, May 26, 2009, 9:01 AM Premarket gainers: MAPP +138%. CYTK +46%. BNC +15%. CPST +13%. HEB +12%. OXGN +9%. UTHR +8%. FEED +7%. Q +6%. ALTI +5%. ARNA +4%.
Losers: TMS +13%. CIM -10%. AIB -7%. GM -6%. CSIQ -6%. FSLR -5%. AIG -5%. DNN -5%. VE -4%. Comment!

Phaeton Falling
$BSPM, $HK, $INTC, $OXGN, $SUNS
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
Bought OXGN had this stock years ago, bought it for $2.00 went up to $20.00! bought now for 0.41 lets see what Happens.
11/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

munchkin
OXGN up today...
12/12/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

kblack4
OXGN, a bipolar turkey?
6/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
OXiGENE (OXGN) rising. You can sell now for a quick 1 hour gain. Not sure how high it will go.
6/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
For a daytrade, buy Oxigene (OXGN) and Clean Diesel Technologies (CDTI).
6/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
6/6/11 8:30 AM ET: So far, the ASCO winners appear to be OXGN & Select BiG Pharma companies.
6/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Oxigene (OXGN) is flying on upcoming meeting about drug. Pharmasset (VRUS) looks a safe buy, but caution on OXGN. http://bit.ly/ifG7Ow
6/4/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Oxigene (OXGN) is surging. Something looks fishy.
5/11/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
(OXGN) 5/10/11 10:30 AM ET: Shares of OXGN continue to recover lost ground & mkt value heading into ASCO. Last: $3.45 [Rx Investors.com]
5/10/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

OXGN OXiGENE, Inc.

OXGN

OXiGENE, Inc.